|
|
Volumn 312, Issue 10, 2014, Pages 987-989
|
|
Largest-ever outbreak of ebola virus disease thrusts experimental therapies, vaccines into spotlight
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
BCX 4430;
EBOLA VACCINE;
MONOCLONAL ANTIBODY;
NUCLEOSIDE DERIVATIVE;
SMALL INTERFERING RNA;
TKM EBOLA;
UNCLASSIFIED DRUG;
ZMAPP;
ARTICLE;
BIOLOGICAL WARFARE AGENT;
CLINICAL TRIAL (TOPIC);
CONSERVATIVE TREATMENT;
DISEASE COURSE;
DRUG APPROVAL;
DRUG EFFICACY;
DRUG RESEARCH;
DRUG SAFETY;
EBOLA HEMORRHAGIC FEVER;
EPIDEMIC;
EXPERIMENTAL THERAPY;
FOOD AND DRUG ADMINISTRATION;
GOVERNMENT REGULATION;
HEALTH CARE ACCESS;
HEALTH CARE FINANCING;
HUMAN;
INFECTION CONTROL;
MORTALITY;
NONHUMAN;
PATIENT MONITORING;
PHASE 1 CLINICAL TRIAL (TOPIC);
POST EXPOSURE PROPHYLAXIS;
RISK BENEFIT ANALYSIS;
RNA INTERFERENCE;
SURVIVAL RATE;
TIME TO TREATMENT;
UNITED STATES;
WORLD HEALTH ORGANIZATION;
NOTE;
DISEASE OUTBREAKS;
EBOLA VACCINES;
HEMORRHAGIC FEVER, EBOLA;
HUMANS;
THERAPIES, INVESTIGATIONAL;
|
|
EID: 84907017597
PISSN: 00987484
EISSN: 15383598
Source Type: Journal
DOI: 10.1001/jama.2014.11170 Document Type: Article |
|
Times cited : (23)
|
|
References (0)
|
